Erlocip Tablet (Erlotinib) – Targeted Therapy for EGFR-Mutated Lung Cancer

Erlocip (Erlotinib) is a prescription targeted oncology medication for the treatment of EGFR mutation-positive non-small cell lung cancer and pancreatic cancer. As a targeted therapy, it works at a molecular level to slow cancer cell proliferation while sparing healthy tissue.

Composition: Erlotinib (150mg)

Manufacturer: Cipla Ltd

Prescription-only oncology medication. Use only under the direct supervision of a licensed oncologist. Regular blood tests and monitoring are mandatory throughout treatment.

Dosage Form	Tablets
Equivalent brand	Tarceva
Generic Name	Erlotinib
Indication	Non-small cell lung cancer, Pancreatic cancer
Manufacturer	Cipla Ltd
Packaging	30 tablets in bottle

RxMed Kart's sole intention is to ensure that its consumers get expert-reviewed, accurate, and trustworthy information. However, the information contained herein should NOT use as a substitute for a qualified physician's advice. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions, or warnings or alerts. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

$190.00

Pack Size

Dose

Quantity

Erlocip Tablet (Erlotinib) – Targeted Therapy for EGFR-Mutated Lung Cancer

Additional information

Disclaimer